Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Gentisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 6/20 | 0.61 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.61 |
| ▸ | CA12 known ✓ | O43570 | 5/20 | 0.61 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.61 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gentisic Acid SCHEMBL453133 | 1.00 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL29564483 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL8084108 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL28741734 | 0.98 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1115092 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL7261031 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL3981502 | 0.95 | CA12 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL10984737 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL344388 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Gentisic Acid SCHEMBL1457617 | 0.95 | CA1 (0.61) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118909611-A | Fracturing fluid, fracturing fluid system, preparation method of fracturing fluid and application of fracturing fluid | 延长油田股份有限公司杏子川采油厂 | 2024-11-08 | — | — | CN | claimed |
| EP-4090350-A1 | SELF-ASSEMBLING PEPTIDE GEL FORMULATION AND METHODS OF USE | Arch Biosurgery, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | PETER MACCALLUM CANCER INST (AU) | 2026-03-19 | — | — | US | disclosed |
| US-12416016-B2 | Adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-09-16 | — | — | US | disclosed |
| US-20250186600-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119384600-A | Method for preparing sample for analysis and analysis method | 株式会社岛津制作所 | 2025-01-28 | — | — | CN | disclosed |
| EP-4493578-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | Peter MacCallum Cancer Institute (AU) | 2025-01-22 | — | — | EP | disclosed |
| CN-118909611-A | Fracturing fluid, fracturing fluid system, preparation method of fracturing fluid and application of fracturing fluid | 延长油田股份有限公司杏子川采油厂 | 2024-11-08 | — | — | CN | disclosed |
| EP-4324482-A2 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | Comera Life Sciences, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11806399-B2 | Excipient compounds for biopolymer formulations | COMERA LIFE SCIENCES, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023173174-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2023-09-21 | — | — | WO | disclosed |
| US-20220401559-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4065166-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | Comera Life Sciences, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114716308-A | Preparation method and application of high-purity gentisic acid | 北京先通国际医药科技股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634412-A | High-purity gentisic acid and application thereof | 北京先通国际医药科技股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114641276-A | Solid compositions comprising a GLP-1 agonist, an SGLT2 inhibitor, and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114641275-A | Solid compositions comprising a PCSK9 inhibitor and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid | 诺和诺德股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11357857-B2 | Excipient compounds for protein processing | COMERA LIFE SCIENCES, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022056220-A2 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | REFORM BIOLOGICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220062423-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077071-A1 | Targeted Delivery of Theranostic Agents | CCKAR, NPY1R, NPY2R | CA1 585/4885CA2 260/4885CA12 220/4885 |
| US-12416016-B2 | Adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor | ASNS, GLUL, SLC3A2 | CA1 2736/4885CA2 3780/4885CA12 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.